Daiichi Sankyo was founded in 2005 and operates in Chuo, Japan. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry belongs to ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by ...

Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells. The drugmaker has teamed up with ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

Prosecutors on Friday called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.

Bernstein analyst Miki Sogi assigned a Buy rating to Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

Las acciones de Daiichi Sankyo cotizan y se negocian en la bolsa de valores Tokio. ¿Cuál es el símbolo bursátil de Daiichi Sankyo? El símbolo bursátil de Daiichi Sankyo es “4568”.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...